GlassScriptPhysician profile
Yesenia E Ochoa
NPI 1962981787
$1,197.65
in general payments reported to CMS, 2019-2025
24 companies · $898 in 2025
The $898 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $34.58 · 2023: $165 · 2024: $99.71 · 2025: $898.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,143 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,142.85 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $185.03 | 2024-2025 | Repatha, Otezla, Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $164.99 | 2025 | |
| Phadia US INC. | $127.55 | 2023 | Immunocap |
| Sumitomo Pharma America, INC. | $91.47 | 2025 | Gemtesa, Myfembree |
| Novo Nordisk INC | $72.34 | 2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $68.94 | 2022-2025 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $58.26 | 2024-2025 | Airsupra |
| Ardelyx, INC. | $55.39 | 2025 | Ibsrela |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.89 | 2025 | Caplyta |
| Recordati_rare_diseases_inc. | $40.54 | 2024-2025 | Isturisa, Signifor Lar |
| Astellas Pharma US INC | $40.50 | 2025 | Veozah |
| Exact Sciences Corporation | $38.22 | 2023-2025 | Cologuard Collection Kit |
| Tonix Medicines, INC. | $21.11 | 2025 | Tonmya |
| Ibsa Pharma INC. | $20.40 | 2025 | Tirosint, Flector, Licart |
| Qiagen, LLC | $19.91 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $19.65 | 2023 | Vaxelis |
| Ascensia Diabetes Care US INC. | $18.90 | 2025 | |
| Cranial Technologies, INC | $18.22 | 2024 | Doc Band |
| Lucid Diagnostics INC. | $17.36 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $16.75 | 2025 | Rexulti |
| Lundbeck LLC | $15.84 | 2025 | Rexulti |
| Corcept Therapeutics | $14.54 | 2025 | Korlym |
| Pfizer INC. | $14.35 | 2025 | |
| Phathom Pharmaceuticals, INC. | $7.50 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yesenia Ochoa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.